Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:14 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 9,942 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Clear all
Completed Phase 3 Interventional Results available

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis

NCT02748512
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Nov 3, 2026, 12:14 PM EST
Completed No phase listed Observational

Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19

NCT04343898
View directory record Official record
Conditions
Coronavirus Infection
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Nov 3, 2026, 12:14 PM EST
Completed Phase 2 Interventional

Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia

NCT00006493
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Rosiglitazone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 12:14 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Chlorhexidine-Alcohol Versus Povidone-Iodine for Cesarean Antisepsis

NCT02202577
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chlorhexidine - Isopropyl alcohol, Povidone-Iodine Scrub and Paint
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
932 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Nov 3, 2026, 12:14 PM EST
Completed Phase 2 Interventional

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads

NCT00036465
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment regimen change
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
23
States / cities
Menlo Park, California • Stanford, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Nov 3, 2026, 12:14 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes

NCT04397900
View directory record Official record
Conditions
Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection, Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types
Interventions
Not listed
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
New Orleans, Louisiana • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Nov 3, 2026, 12:14 PM EST
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

NCT04652700
View directory record Official record
Conditions
HIV Preexposure Prophylaxis
Interventions
ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 3, 2026, 12:14 PM EST
Completed Phase 1Phase 2 Interventional Results available

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

NCT00558844
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Arikayce™ 560 mg, Placebo for 560 mg, Arikayce™ 70 mg, Arikayce™ 140 mg, Placebo for 70 mg / 140 mg
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
6 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Nov 3, 2026, 12:14 PM EST
Withdrawn Phase 2 Interventional

Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

NCT05269134
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
Bacteriophage, Placebo
Drug
Lead sponsor
Adaptive Phage Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
San Diego, California • Hartford, Connecticut • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Nov 3, 2026, 12:14 PM EST
Completed Phase 3 Interventional Results available

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

NCT00711009
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection
Interventions
lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Nov 3, 2026, 12:14 PM EST
Completed Phase 3 Interventional Results available

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

NCT00412893
View directory record Official record
Conditions
Aspergillosis, Invasive Fungal Infection
Interventions
Isavuconazole, Voriconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Nov 3, 2026, 12:14 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Nov 3, 2026, 12:14 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Inflammation and Cardiovascular Health in Women

NCT04224181
View directory record Official record
Conditions
HIV/AIDS, Myocardial Infarction
Interventions
Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 79 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Nov 3, 2026, 12:14 PM EST
Completed No phase listed Observational

A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements

NCT00001077
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Multivitamin and mineral supplements, Peptamen, NuBasics
Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Nov 3, 2026, 12:14 PM EST
Suspended Not applicable Interventional Accepts healthy volunteers

Changes in Cellular Immune Profile During COVID-19 Infection

NCT04470999
View directory record Official record
Conditions
Covid19, SARS-CoV-2
Interventions
Leukapheresis
Other
Lead sponsor
Serhat Gumrukcu, MD PhD
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Nov 3, 2026, 12:14 PM EST
Completed Phase 1 Interventional

A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP

NCT00000998
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 3, 2026, 12:14 PM EST
Not listed Phase 1 Interventional

Treatment of Advanced AIDS Patients With Dextrin Sulfate

NCT00004987
View directory record Official record
Conditions
HIV Infections
Interventions
Dextrin 2-sulfate
Drug
Lead sponsor
Steinhart Medical Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 12:14 PM EST
Completed No phase listed Observational

Immune Activity Against CVM Retinitis

NCT00001611
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis, HIV Infection
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 12:14 PM EST
Completed No phase listed Observational

Etiology of Eczema Herpeticum (EH)

NCT03038932
View directory record Official record
Conditions
Eczema Herpeticum
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 64 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Nov 3, 2026, 12:14 PM EST
Completed Not applicable Interventional

One Stage Versus Two Stage For Periprosthetic Hip And Knee Infection

NCT02734134
View directory record Official record
Conditions
Surgical Site Infection
Interventions
One-stage exchange joint replacement surgery, Two-stage exchange joint replacement surgery
Procedure
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 3, 2026, 12:14 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Transplacental Transmission of RSV (TTRSV)

NCT05443607
View directory record Official record
Conditions
SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
2
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 3, 2026, 12:14 PM EST
Completed Phase 3 Interventional Results available

Cholecalciferol Supplementation for Sepsis in the ICU

NCT01896544
View directory record Official record
Conditions
Hypovitaminosis D
Interventions
Cholecalciferol, Placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Nov 3, 2026, 12:14 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Nov 3, 2026, 12:14 PM EST
Active, not recruiting No phase listed Observational

Pain in Long COVID-19: The Role of Sleep

NCT05606211
View directory record Official record
Conditions
Long COVID
Interventions
No intervention
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 12:14 PM EST